Detalles de la búsqueda
1.
Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060.
JTO Clin Res Rep;
5(4): 100655, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38706978
2.
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Jpn J Clin Oncol;
54(4): 452-462, 2024 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38271158
3.
Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases.
Cancer Rep (Hoboken);
7(2): e1981, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38212894
4.
Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase.
Adv Ther;
40(11): 4928-4944, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37715851
5.
Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge.
Thorac Cancer;
14(31): 3140-3146, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37699787
6.
Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial.
BMC Cancer;
22(1): 964, 2022 Sep 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36076179
7.
Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L).
Clin Cancer Res;
: OF1-OF7, 2022 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35762926
8.
Anti-nuclear antibody and a granuloma could be biomarkers for iCIs-related hepatitis by anti-PD-1 treatment.
Sci Rep;
12(1): 3669, 2022 03 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35256688
9.
Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
Oncologist;
27(5): e410-e419, 2022 05 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35348766
10.
Association between immune-related adverse event timing and treatment outcomes.
Oncoimmunology;
11(1): 2017162, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35003896
11.
Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers.
PLoS One;
16(11): e0260500, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34843570
12.
Prospective Multicenter Study of Chemotherapy-Induced Clostridium (Clostridioides) difficile Infection in Patients With Lung Cancer: North Japan Lung Cancer Study Group Trial 1204.
Front Oncol;
11: 685320, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34336670
13.
Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
Cancer Med;
10(14): 4796-4804, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34121358
14.
Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001.
Transl Lung Cancer Res;
10(2): 712-722, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33718016
15.
Serial 6-month change in forced vital capacity predicts subsequent decline and mortality in Japanese patients with newly diagnosed idiopathic pulmonary fibrosis.
Respir Investig;
59(3): 335-341, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33551330
16.
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
JAMA Oncol;
7(3): 386-394, 2021 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33410885
17.
Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab.
JMA J;
3(1): 58-66, 2020 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33324776
18.
A Remarkable Clinical Response to Pembrolizumab in a Rare Spindle Cell Carcinoma of the Lung.
JMA J;
3(1): 83-86, 2020 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33324781
19.
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
JAMA Oncol;
6(12): 1952-1956, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33119034
20.
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Cancer Immunol Immunother;
69(7): 1189, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32347358